Kingenic focuses on developing, personalizing and making critical therapeutics accessible for patients across a wide range of treatments. We have several key areas of focus where our specialty research and development concentrates it efforts. There are treatments for respiratory, pain and migraine, neurodegenerative conditions and movement disorders, oncology and cardiology.
Today, 300 million people globally suffer from asthma and chronic lung diseases, suffering attacks of breathlessness and wheezing. Kingenic aims to provide supply of medicines on the World Health Organization’s (WHO) Essential Medicines List for respiratory conditions. While these diseases are often chronic, the greatest assistance for those living with these conditions is to provide a treatment which can be carried with them and can be administered as efficiently as possible. Accordingly, key to our work developing asthma treatments is improving the efficiency of inhalers for both maintenance and rescue therapies. Our innovative and growing portfolio of digitally integrated combination treatment options has the potential to change the future of care for the respiratory community.
Migraine, Headache and Pain
About a billion people around the world are affected by pain & migraines. Many suffer from severe headaches, and others endure debilitating pain, blurred vision and other side-effects, some for as many as 15 days a month or more. Kingenic has been providing treatments for diseases of the central nervous system for targeted therapy and helping people live a better life. We are working to bring innovative treatments to those suffering from migraine and headache, as well as bringing greater awareness of the impact these conditions can have on peoples’ lives. We also believe there is significant unmet need in chronic pain associated with osteoarthritis, and that new medicines are needed for appropriate patients.
Neurodegenerative Conditions and Movement Disorders
There can be many challenges - physically, financially, and emotionally - faced every day by people living with diseases of the central nervous system and their families. Neurodegenerative conditions and movement disorders such as multiple sclerosis (MS), Parkinson’s Disease (PD), Huntington’s Disease (HD) and Tardive Dyskinesia (TD) affect every aspect of life, with even the most mundane tasks requiring great courage and effort. It is expected that by 2030, we will see a rise of between 30-50% in the incidence of such diseases, with an associated need for increased treatment and care. Kingenic is developing a number of products to treat patients with neurological and neurodegenerative disorders – with a focus on helping patients manage their condition.
When a patient is told they have cancer, their world – and the worlds of their families and loved ones – is turned upside down. within addition to coping with the illness itself, the side-effects of the prescribed treatment can also be harrowing and difficult. Yet, thankfully, there have been tremendous advancements in care in recent years. Kingenic is dedicated to make a profound difference in the lives of people with cancer.
Kingenic is focused to develop and provide affordable generic options to a variety of complex molecules for oncology including treatment for chronic forms of leukaemia and types of non-Hodgkin’s lymphoma, among other types of cancer. Kingenic is also committed to developing and marketing biosimilars, with the potential to create lower healthcare costs. This focus is consistent with Kingenic’s mission of making accessible medications to help improve the lives of patients.